Prof Dimitrios P Bogdanos
@DBogdanos
Followers
594
Following
2K
Media
73
Statuses
782
Physician, autoimmunologist and Director, Rheumatology & Clin Immunology, Univ of Thessaly Med. School,,Greece Editor-in-Chief Autoimmunity Reviews,
Larissa, Greece
Joined January 2020
You can always find something interesting to Read
Check out the latest issue of MJR!!.🔹 Infrared Thermography in RMDs.🔹 Cortisol & RA outcomes.🔹 Anti-TIF1γ myositis.🔹 What do rheumatologists know about reproductive health?.and much more!!
1
3
6
RT @MJR_journal: Check out the latest issue of MJR!!.🔹 Infrared Thermography in RMDs.🔹 Cortisol & RA outcomes.🔹 Anti-TIF1γ myositis.🔹 What….
0
9
0
🧬 #SystemicSclerosis (SSc) shows a clear sex bias: A narrative review that discusses the issue in depth! #SystemicSclerosis #SSc #AutoimmuneDisease #SexDifferences #AutoimmuneResearch #Immunology #Fibrosis #LungDisease
0
2
13
🚨 New meta-analysis: Circulating follicular helper T (cTfh) cells are significantly increased in SLE patients, highlighting their role in disease development. Elevated cTfh may be promising biomarkers? 🔬🩺 #Autoimmunity #SLE #Immunology #Research
0
14
16
Indeed a unique opportunity to disseminate your research in rheumatology and have an impact!.
The @MJR_journal is Platinum Access!.This means no fees for submitting, processing and publishing your manuscript and all content access without a subscription! We are indexed in #Pubmed, #Scopus, #Embase, #WebofScience. and now we have an impact factor!.
0
2
6
🚀 Discover the Promising Role of GLP-1 Antagonists in Rheumatology: the pros and cons! A joint recent publication with Drs Bilgin and Venerito that I really enjoyed!.
🚀🚀🚀🚀.‼️‼️Fresh publication‼️‼️. 👉👉GLP-1 RAs are the hot topics of recent years. 👉👉They are promising effects in rheumatologic diseases. ⚠️Robust evidence is needed. First of fruitful collaborations with @DBogdanos @vincevenerito . @sakaryauni @ElsevierTurkiye
0
5
23
From the Editor-in-Chief: Autoimmunity Reviews maintains its strong performance with a new impact factor of 8.3, marking an unprecedented level of influence in the field of Autoimmunity.Congratulations to all. #AutoimmunityReviews #ImpactFactor #ResearchExcellence
3
5
21
The last lecture, of the last semester of the last year of our 6th year undergraduates of our Medical School. So proud of !!!! #MedicalStudents #ThessalyUniversity #MedicalEducation #FutureDoctors #MedSchoolLife #HealthScience #MedicalStudentsGreece #MedStudentLife #MedicalSchool
1
0
6
Probably the only Open Access Platinum (no publications fees), Pubmed Indexed Rheumatology Journal with an Impact Factor!!! Congratulations and next year even better!!1.
🎉 Big milestone for the Mediterranean Journal of Rheumatology!.We are proud to announce our first-ever Impact Factor: 1.4 (JCR 2024) 📊✨.This achievement reflects the dedication of our authors, reviewers, and editorial team — thank you for being part of this journey!
1
8
16
RT @MJR_journal: 🎉 Big milestone for the Mediterranean Journal of Rheumatology!.We are proud to announce our first-ever Impact Factor: 1.4….
0
12
0
With my good friends and co-patriots George Tsokos (Harvard) & Petros Sfikakis (Athens) at @eular_org Barcelona
0
1
18
With George (Tsokos) Harvard and Petros (Sfikakis) Athens at Barcelona
0
0
5
EULAR 2025 at Barcelona was a venue giving me the opportunity to make new friends and initiate new projects. With @dr_emrebilgin from Turkey
1
5
14
Barcelona's EULAR 2025 is close to the end! Approximately 7000 clinicians and scientists from all over the world celebrate the latest in Rheumatology
0
0
7
7/.📄 Full study:.Tsiogkas SG et al. Autoimmun Rev. 2025 Apr 21;24(6):103819. PMID: 40268128.Thanks for reading!.#RheumTwitter #MedTwitter #JAKinhibitors #PsA #SystematicReview.
0
0
3
6/.✨ Bottom line:.✅ Upadacitinib may offer clinical advantages in some PsA domains.⚠️ But more data are needed to fully assess long-term safety.🧠 Informed choices matter more than ever.
0
0
1
5/.📈 Why this matters:.Our study provides the first head-to-head evidence synthesis of current JAKi options in PsA. It highlights differential efficacy, but reminds us (to me):.🔍 One size doesn’t fit all. #PersonalizedMedicine #Autoimmunity.
0
0
2
4/ ☣️ Safety?.The rate of serious adverse events (SAEs) was comparable across JAKis, including upadacitinib. ➡️ No clear leader in safety, underscoring the need for individual risk–benefit decisions.
0
0
0
2/.⚖️ Most JAKis outperformed placebo in all efficacy outcomes. However, upadacitinib stood out with statistical superiority in: ACR50 & ACR70, PASI75, dactylics .☣️ Safety?. keep reading.
0
0
1
2/.📚 We included randomized controlled trials from:.MEDLINE. CENTRAL.Web of Science.(up to Oct 2023).Outcomes: ACR20/50/70, PASI75, enthesitis/dactylitis resolution, HAQ-DI, and SAEs. #EvidenceBasedMedicine.
0
0
1